Summary
- Profile Type
- Technology offer
- POD Reference
- TOFR20230316001
- Term of Validity
- 16 March 2023 - 15 March 2025
- Company's Country
- France
- Type of partnership
- Research and development cooperation agreement
- Commercial agreement with technical assistance
- Investment agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A French biotech SME has developed a strong expertise in the analysis of the microbiota of low biomass samples beyond the intestinal microbiota. The analysis of the microbiota makes it possible to better understand the appearance and evolution of diseases, to develop biomarkers and innovative treatments. The company is seeking new customers and international partners (public or private) for European grant applications.
- Full Description
-
The study of the microbiota has become central to biomedical research. The analysis of the microbiota makes it possible to better understand the appearance and evolution of diseases, to develop biomarkers and innovative treatments. The market today mainly targets the intestinal microbiota, even if microbiotas exist throughout the human body. These tissue and blood microbiotas are more complex analysis but offers significant scientific potential in terms of precise information and therapeutic outlets.
The French biotech SME is one of the few players in the world with expertise in the analysis of the microbiota of low biomass samples, beyond the intestinal microbiota.
It offers microbiome, metagenome and microbiota analyses in all types of human and animal samples including low biomass samples (tissues, cancerous tumors, skin, and blood) and high biomass (gut, feces, saliva, lung vagina).
This innovation in complex microbiota (blood, skin, urine, saliva, liver biopsies, tumors, etc.) makes it possible to be closer to disease mechanisms for predictive diagnostic strategies and personalized medicine.
The company business is based on service offer for microbiome analysis (wet lab, sequencing, bioinformatics, statistical analysis, and scientific support) which is associated with strong collaborative research activity. The company is the principal private partner of two major international European granted consortia (H2020 and ERDF), obtained several grants from the French government, and have published 40 peer-review articles in high impact factor journals (role of microbiome in cancer, hepatology, cardiometabolic diseases, infectiology, Lyme disease …).
The expertise in microbiome can be used in any area of health research, but the expertise of company in tissue and blood samples is particularly interesting for applications in cancer (tumor and liquid biopsy), disease with a major role of bacterial translocation (liver diseases, cardiometabolic disease, HIV, autoimmune disease, leaky gut, IBD- Inflammatory Bowel Disease, …) and challenging sample types (skin, saliva, swab, body fluid, small biopsies, …)
The company’s business model is based on service offer for microbiome analysis (wet lab, sequencing, bioinformatics and scientific support) and is associated with strong collaborative research activity.
The company offers its services and expertise for the discovery of new disease mechanisms, new biomarkers to contribute to personalized medicine and new pathways to identify novel therapeutic targets in the frame of European calls of project with public or private partners (mostly as partner to joint coordinator and consortium) or commercial agreements with technical expertise. The company is also seeking investors to finance the company commercial upscaling or the industrialization of secured intellectual properties. - Advantages and Innovations
-
The technological breakthrough of the company was perfected after 10 years of R&D. The analysis solutions are now used by research players all over the world as innovative tools for scientific discovery.
The company can analyze the microbiome in all types of samples and matrices but is the pioneer and a major actor of low biomass sample analysis with a dedicated and tissue-specific contamination aware approach. The pipeline of analysis is really sensitive and exhaustive.
The technological platform and the scientific advice cover all steps of the analysis of human or animal samples.
Expertise of the company is perfectly suitable for both experts of the microbiome which want to access new sample types or for clinicians, academic researchers and industrial without expertise of the field and needing a high-end technical and scientific support.
Studying the different microbiota of the organism, allow to obtain more exploitable data, to be closer to the disease mechanism, and to discover biomarkers accessible in liquid biopsy (blood, urine, saliva). - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 9: Industry, Innovation and Infrastructure
- Goal 17: Partnerships to achieve the Goal
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
-
The company is seeking partners working on the discovery of new disease mechanisms, new biomarkers to contribute to personalized medicine and new pathways to identify novel therapeutic targets.
Virtually all thematic of health science could be linked to microbiome, and the company is used to working with experts of numerous expertise. However, several thematic are more developed such as cancer, hepatology and infectious diseases (in particular Lyme disease and tick-borne diseases).
The partners may be clinicians, academic or industrial partners needing microbiome expertise and analysis capabilities for their own research or applications (basic science, biomarkers and therapeutic target discovery, impact of existing treatment and drugs, …). Partners could be a consortium of researchers and academic labs which want to include metagenomics analysis in their projects, clinician teams with cohorts of patients with disease related to microbiota, or industrial needing to assess the impact of their product on microbiome.
The company may also provide these analyses to experts of the microbiota field to study low biomass samples and tumor microbiome or to experts of other fields needing a comprehensive pipeline and high-end support to study microbiome in easy (gut, skin, ...) or challenging samples (blood, tissue, …).
The company is also looking for investors to finance its commercial development in a growing market, and t the industrialization of secured intellectual properties (biomarkers of different diseases, and expertise in low biomass microbiome analysis). - Type and Size of Partner
- University
- Big company
- SME <=10
- Other
- SME 50 - 249
- SME 11-49
- R&D Institution
- Type of partnership
- Research and development cooperation agreement
- Commercial agreement with technical assistance
- Investment agreement
Dissemination
- Technology keywords
- 06002002 - Cellular and Molecular Biology
- 06002008 - Microbiology
- 06003001 - Bioinformatics
- Market keywords
- 05001007 - Other diagnostic
- 04009 - In vitro Testing, Trials
- 04010 - Microbiology
- 04006 - Cellular and Molecular Biology
- Sector Groups Involved
- Health
- Targeted countries
- All countries